Randomized trial · people

LL-37 taken by mouth shortened time to negative COVID-19 RNA test

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This is a randomized human trial of an oral LL-37 product in which early treatment of hospitalized Omicron patients was linked to faster clearance of virus RNA without severe side effects.

Kind
Randomized trial
Studied in
People
Number studied
238
Published
2023
Journal
J Med Virol

What they tested

Researchers tested whether Oral LL-37, a recombinant Lactococcus lactis product taken by mouth, could speed clearance of an Omicron subvariant of SARS-CoV-2 and whether it was safe.

How the study was done

An open-label, randomized, placebo-controlled trial at a single center in 238 adults hospitalized with COVID-19. Open-label means patients and doctors knew who got which treatment. The main outcomes were negative conversion time, how long until tests no longer found the virus's RNA, and side effects.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

When started by day 6 after the case was confirmed, Oral LL-37 shortened negative conversion time to 9.80 ± 2.67 versus 14.04 ± 5.89 with placebo (p < 0.01). Among people on Oral LL-37, starting within 6 days gave an adjusted hazard ratio for a negative test of 6.276 (95% CI 3.631-10.848) compared with starting later. Starting within 6 days also beat placebo, with a hazard ratio of 2.427 (95% CI 1.239-4.751). No severe side effects were seen during the hospital stay or follow-up.

What it doesn’t show

Patients and staff knew who got which treatment, and the trial ran at a single hospital in inpatients with one Omicron subvariant. It measured how fast virus RNA cleared and safety, not other outcomes such as symptoms.

The paper

Zhao et al. Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial. J Med Virol. 2023.

The compound

More studies on LL-37

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo